--- - - --- - - ---
2024-05-31
- - - - - - - -
Plasma Glutathione
Levels Decreased with Cognitive Decline among People with Mild Cognitive
Impairment (MCI): A Two-Year Prospective Study PY2021 IR95 IR96 Taiwan
Plasma Glutathione Levels Decreased with Cognitive Decline among People with
Mild Cognitive Impairment (MCI): A Two-Year Prospective Study PY2021 IR95 IR96 Taiwan
在 輕度認知障礙的患者 中，血漿裡面的 穀胱甘肽 之水平 隨著 認知能力 的下降而逐漸減少：一個為期兩年的前瞻性研究計畫
資訊來源 2024-0522：
https://pubmed.ncbi.nlm.nih.gov/34829710/
#湯偉晉挑選的醫學論文
##
Antioxidants (Basel)
2021 Nov 19;10(11):1839. doi: 10.3390/antiox10111839.
Plasma Glutathione Levels Decreased with Cognitive Decline among People with
Mild Cognitive Impairment (MCI): A Two-Year Prospective Study
Chieh-Hsin Lin 1 2 3, Hsien-Yuan Lane 3 4 5
Affiliations collapse
Affiliations
1
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung
University College of Medicine, Kaohsiung 83301, Taiwan. 長庚大學醫學院高雄長庚醫院精神科，台灣高雄
2
School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan 長庚大學醫學院, 台灣 桃園
3
Graduate Institute of Biomedical Sciences, China Medical University, Taichung
40402, Taiwan. 中國醫藥大學，台中
4
Department of Psychiatry & Brain Disease Research Center, China Medical University
Hospital, Taichung 40402, Taiwan.
5
Department of Psychology, College of Medical and Health Sciences, Asia
University, Taichung 41354, Taiwan.
PMID: 34829710
PMCID: PMC8615204
DOI: 10.3390/antiox10111839
Abstract
Glutathione (GSH) is a
major endogenous antioxidant. Several studies have shown GSH redox
imbalance and altered GSH levels in Alzheimer's disease (AD) patients. Early detection is crucial for
the outcome of AD. However,
whether GSH can serve as a biomarker during the very early-phase of AD, such as
mild cognitive
impairment (MCI),
remains unknown. The current prospective study aimed to examine the
longitudinal change in plasma GSH concentration and its influence on cognitive decline in MCI.
Overall, 49 patients with MCI and 16 healthy individuals were recruited. Plasma
GSH levels and cognitive function, measured by the Mini-Mental Status
Examination (MMSE) and Alzheimer's disease assessment scale-cognitive subscale
(ADAS-cog), were monitored every 6 months. We employed multiple regressions to examine the role of
GSH level in cognitive decline in the 2 years period. The MCI patients showed
significant decline in plasma GSH levels and cognitive function from baseline
to endpoint (month 24). In comparison, the healthy individuals' GSH concentration
and cognitive function did not change significantly. Further, both GSH level at baseline
and GSH level change from baseline to endpoint significantly influenced
cognitive decline among the MCI patients. To our knowledge, this is the first study to demonstrate
that both plasma GSH levels and cognitive function declined 2 years later among
the MCI patients in a prospective manner. If replicated by future studies,
blood GSH concentration may be regarded as a biomarker for monitoring cognitive
change in MCI.
Begin_電腦自動翻譯的內容_Y2024M05D31H03M27Rn3488_
(請注意：電腦自動翻譯的內容，可能會夾雜一些錯誤！)
穀胱甘肽 (GSH) 是一種主要的內源性抗氧化劑。多項研究表明，阿茲海默症 (AD) 患者存在 GSH 氧化還原失衡和 GSH 水平改變。早期發現對於 AD 的結果至關重要。然而，GSH 是否可以作為 AD 早期階段（例如輕度認知障礙（MCI））的生物標記仍不清楚。目前的前瞻性研究旨在探討血漿 GSH 濃度的縱向變化及其對 MCI 認知能力下降的影響。總體而言，招募了 49 名 MCI 患者和 16 名健康個體。每 6 個月監測血漿 GSH 水平和認知功能，並透過簡易精神狀態檢查 (MMSE) 和阿茲海默症評估量表-認知分量表 (ADAS-cog) 進行測量。我們採用多元迴歸來檢驗 GSH 水準在兩年內認知能力下降中的作用。 MCI 患者的血漿 GSH 水平和認知功能從基線到終點（第 24 個月）顯著下降。相較之下，健康個體的GSH濃度和認知功能則沒有顯著變化。此外，基線時的 GSH 水平以及從基線到終點的 GSH 水平變化均顯著影響 MCI 患者的認知能力下降。據我們所知，這是第一個前瞻性地證明 MCI 患者血漿 GSH 水平和認知功能在 2 年後下降的研究。如果未來的研究能夠重複，血液 GSH 濃度可能被視為監測 MCI 認知變化的生物標記。
End_電腦自動翻譯的內容_Y2024M05D31H03M27Rn3488_
Keywords: Alzheimer’s disease (AD); biomarker; cognitive function; glutathione
(GSH); mild cognitive impairment (MCI).
PubMed Disclaimer
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the
design of the study; in the collection, analyses, or interpretation of data; in
the writing of the manuscript, or in the decision to publish the results.
Similar articles
Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People
With Mild Cognitive Impairment: A Two-Year Prospective Study.
Lin CH, Lane HY.
Int J Neuropsychopharmacol. 2022 Aug 16;25(8):660-665. doi:
10.1093/ijnp/pyac027.
PMID: 35430632 Free PMC article.
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the
U.S. Preventive Services Task Force [Internet].
Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov.
Report No.: 14-05198-EF-1.
PMID: 24354019 Free Books & Documents. Review.
Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild
cognitive impairment and mild Alzheimer's disease: change over time and the
effect of enrichment strategies.
Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging
Initiative.
Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.
PMID: 26868820 Free PMC article.
Validation study of the Alzheimer's disease assessment scale-cognitive subscale
(ADAS-Cog) for the Portuguese patients with mild cognitive impairment and
Alzheimer's disease.
Nogueira J, Freitas S, Duro D, Almeida J, Santana I.
Clin Neuropsychol. 2018 Jan-Dec;32(sup1):46-59. doi:
10.1080/13854046.2018.1454511. Epub 2018 Mar 23.
PMID: 29566598
Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N, Llewellyn D, Isaac MGEKN, Tabet N.
Cochrane Database Syst Rev. 2017 Apr 18;4(4):CD002854. doi:
10.1002/14651858.CD002854.pub5.
PMID: 28418065 Free PMC article. Review.
See all similar articles
Cited by
Blood Biomarkers in Alzheimer's Disease.
Mandal PK, Maroon JC, Garg A, Arora NK, Bansal R, Kaushik A, Samkaria A,
Kumaran G, Arora Y.
ACS Chem Neurosci. 2023 Nov 15;14(22):3975-3978. doi:
10.1021/acschemneuro.3c00641. Epub 2023 Oct 25.
PMID: 37878665 Free PMC article.
Differential Impacts of Endogenous Antioxidants on Clinical Symptoms and
Cognitive Function in Acute and Chronic Schizophrenia Patients.
Lin CH, Li TM, Huang YJ, Chen SJ, Lane HY.
Int J Neuropsychopharmacol. 2023 Aug 29;26(8):576-583. doi:
10.1093/ijnp/pyad040.
PMID: 37422918 Free PMC article.
Precious but convenient means of prevention and treatment: physiological
molecular mechanisms of interaction between exercise and motor factors and
Alzheimer's disease.
Hao Z, Liu K, Zhou L, Chen P.
Front Physiol. 2023 Jun 8;14:1193031. doi: 10.3389/fphys.2023.1193031.
eCollection 2023.
PMID: 37362440 Free PMC article. Review.
Crosstalk between Oxidative Stress and Aging in Neurodegeneration Disorders.
Abdelhamid RF, Nagano S.
Cells. 2023 Feb 27;12(5):753. doi: 10.3390/cells12050753.
PMID: 36899889 Free PMC article. Review.
Non-Enzymatic Antioxidants against Alzheimer's Disease: Prevention, Diagnosis
and Therapy.
Varesi A, Campagnoli LIM, Carrara A, Pola I, Floris E, Ricevuti G, Chirumbolo
S, Pascale A.
Antioxidants (Basel). 2023 Jan 12;12(1):180. doi: 10.3390/antiox12010180.
PMID: 36671042 Free PMC article. Review.
See all "Cited by" articles
References
Hinton L., Nguyen H., Nguyen H.T., Harvey D.J., Nichols L., Martindale-Adams
J., Nguyen B.T., Nguyen A.N., Nguyen C.H., Nguyen T.T.H., et al. Advancing
family dementia caregiver interventions in low- and middle-income countries: A
pilot cluster randomized controlled trial of Resources for Advancing
Alzheimer’s Caregiver Health in Vietnam (REACH VN) Alzheimer’s Dement. Transl.
Res. Clin. Interv. 2020;6:e12063. doi: 10.1002/trc2.12063. - DOI - PMC -PubMed
Schrag M., Mueller C., Zabel M., Crofton A., Kirsch W., Ghribi O., Squitti R.,
Perry G. Oxidative stress in blood in Alzheimer’s disease and mild cognitive
impairment: A meta-analysis. Neurobiol. Dis. 2013;59:100–110. doi:
10.1016/j.nbd.2013.07.005. - DOI - PubMed
Zarrouk A., Hammouda S., Ghzaiel I., Hammami S., Khamlaoui W., Ahmed S.H.,
Lizard G., Hammami M. Association Between Oxidative Stress and Altered
Cholesterol Metabolism in Alzheimer’s Disease Patients. Curr. Alzheimer Res.
2021;17:823–834. doi: 10.2174/1567205017666201203123046. - DOI - PubMed
Cheng Y.-J., Lin C.-H., Lane H.-Y. Involvement of Cholinergic, Adrenergic, and
Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s
Disease. Int. J. Mol. Sci. 2021;22:2283. doi: 10.3390/ijms22052283. - DOI - PMC
- PubMed
Kamat P.K., Kalani A., Rai S., Swarnkar S., Tota S., Nath C., Tyagi N.
Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of
Alzheimer’s Disease: Understanding the Therapeutics Strategies. Mol. Neurobiol.
2014;53:648–661. doi: 10.1007/s12035-014-9053-6. - DOI - PMC - PubMed
##
- - - - -- -- - -
--- --- - - --- ---
